Thrombolex develops the BASHIR™ family of endovascular catheters, which utilize a hybrid mechanism of action combining mechanical and pharmacological treatments to restore blood flow in patients with arterial and venous thromboembolic conditions. This technology enables efficient thrombolytic delivery, reducing procedure time and improving clinical outcomes for conditions such as acute pulmonary embolism.
Funding
$23.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for treating arterial and venous thromboembolic conditions often fail to efficiently restore blood flow and maximize clot resolution, potentially leading to inconsistent clinical outcomes and prolonged procedure times. Single-lumen catheter-directed thrombolysis (CDT) devices limit the surface area of thrombus exposed to lytics, hindering rapid and effective thrombolysis.
Solution
Thrombolex develops the BASHIR™ family of endovascular catheters, which employ a hybrid mechanism combining mechanical clot fragmentation and targeted pharmacological thrombolysis to immediately restore blood flow in patients with thromboembolic conditions. The expandable nitinol-enhanced infusion basket creates fissures within the thrombus, increasing the surface area exposed to both endogenous and exogenous thrombolytics. This design facilitates the controlled and selective infusion of physician-specified fluids, including thrombolytics, directly into the thrombus via multiple mini-infusion catheters, promoting rapid flow restoration and efficient thrombus lysis. The BASHIR™ system aims to simplify procedures, optimize outcomes, and improve safety in the treatment of arterial and venous thromboembolic diseases.
Target Audience
The primary target audience includes interventional cardiologists, interventional radiologists, and vascular surgeons treating patients with arterial and venous thromboembolic conditions, such as pulmonary embolism, iliofemoral thrombosis, and acute limb ischemia.
Features
- Expandable nitinol-enhanced infusion basket that expands from 2.3mm up to 45mm to create cross-sectional fissures and fragment the thrombus
- Multiple (6) mini-infusion catheters within the expandable basket, each with 8 laser-drilled infusion holes, for targeted delivery of thrombolytics
- Hybrid mechanism of action combining mechanical clot fragmentation and targeted pharmacological thrombolysis
- Compatibility with a 0.035" guidewire for the treatment of acute pulmonary embolism
- Available in 7F and 8F sizes
- Designed for on-table pharmacomechanical lysis (PML) without post-procedural thrombolytic infusion